î
îŒ
î
111 Inc
YI3.160USD
-0.533-14.44%
çµå€Â 12/22, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
160.13Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± 111 Inc äŒæ¥å
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Companyâs products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
111 Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãYI
äŒç€Ÿå111 Inc
äžå Žæ¥Sep 12, 2018
æé«çµå¶è²¬ä»»è
ãCEOãLiu (Junling)
åŸæ¥å¡æ°1238
蚌åžçš®é¡Depository Receipt
決ç®ææ«Sep 12
æ¬ç€Ÿæåšå°3-4/F, No.295 Zuchongzhi Road
éœåžSHANGHAI
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœChina
éµäŸ¿çªå·201203
é»è©±çªå·862120536666
ãŠã§ããµã€ãhttp://corporate.111.com.cn/
äŒæ¥ã³ãŒãYI
äžå Žæ¥Sep 12, 2018
æé«çµå¶è²¬ä»»è
ãCEOãLiu (Junling)
111 Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
æ ªäž»
æŽæ°æå»: Tue, Dec 2
æŽæ°æå»: Tue, Dec 2
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
First Pharmacia International
8.57%
Susquehanna International Group, LLP
0.59%
Renaissance Technologies LLC
0.26%
Morgan Stanley & Co. LLC
0.10%
Geode Capital Management, L.L.C.
0.05%
ä»ã®
90.43%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
First Pharmacia International
8.57%
Susquehanna International Group, LLP
0.59%
Renaissance Technologies LLC
0.26%
Morgan Stanley & Co. LLC
0.10%
Geode Capital Management, L.L.C.
0.05%
ä»ã®
90.43%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Private Equity
15.64%
Corporation
8.57%
Venture Capital
7.15%
Investment Advisor
0.62%
Hedge Fund
0.26%
Research Firm
0.11%
Investment Advisor/Hedge Fund
0.05%
ä»ã®
67.61%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
42
1.21M
23.79%
-403.88K
2025Q2
48
1.99M
39.33%
-416.92K
2025Q1
49
2.00M
39.53%
-387.91K
2024Q4
51
2.26M
44.72%
+133.67K
2024Q3
43
1.99M
39.36%
-280.22K
2024Q2
45
2.17M
42.88%
-87.92K
2024Q1
52
2.15M
42.65%
-125.45K
2023Q4
54
2.16M
44.89%
-28.04K
2023Q3
57
2.15M
44.81%
-47.43K
2023Q2
64
2.05M
43.37%
+895.26K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
First Pharmacia International
434.53K
8.57%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
14.77K
0.29%
+14.77K
--
Jun 30, 2025
Renaissance Technologies LLC
13.01K
0.26%
+200.00
+1.56%
Jun 30, 2025
Morgan Stanley & Co. LLC
5.14K
0.1%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
6.12K
0.12%
+4.66K
+320.77%
Jun 30, 2025
SBI Securities Co., Ltd.
224.00
0%
-38.00
-14.50%
Jun 30, 2025
J.P. Morgan Securities LLC
8.00
0%
-62.00
-88.57%
Jun 30, 2025
Parametric Portfolio Associates LLC
27.00
0%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
22.00
0%
--
--
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
SPDR S&P Emerging Markets Small Cap ETF
0%
SPDR Portfolio Emerging Markets ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
æ¯ç0%
SPDR Portfolio Emerging Markets ETF
æ¯ç0%
SPDR S&P Emerging Asia Pacific ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
æ¥ä»
çš®é¡
æ¯ç
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
Jan 03, 2025
Merger
10â1
ãããã質å
111 Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
î111 Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
First Pharmacia Internationalã¯434.53Kæ ªãä¿æããŠãããããã¯å šäœã®8.57%ã«çžåœããŸãã
Susquehanna International Group, LLPã¯14.77Kæ ªãä¿æããŠãããããã¯å šäœã®0.29%ã«çžåœããŸãã
Renaissance Technologies LLCã¯13.01Kæ ªãä¿æããŠãããããã¯å šäœã®0.26%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯5.14Kæ ªãä¿æããŠãããããã¯å šäœã®0.10%ã«çžåœããŸãã
UBS Financial Services, Inc.ã¯6.12Kæ ªãä¿æããŠãããããã¯å šäœã®0.12%ã«çžåœããŸãã
First Pharmacia Internationalã¯434.53Kæ ªãä¿æããŠãããããã¯å šäœã®8.57%ã«çžåœããŸãã
Susquehanna International Group, LLPã¯14.77Kæ ªãä¿æããŠãããããã¯å šäœã®0.29%ã«çžåœããŸãã
Renaissance Technologies LLCã¯13.01Kæ ªãä¿æããŠãããããã¯å šäœã®0.26%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯5.14Kæ ªãä¿æããŠãããããã¯å šäœã®0.10%ã«çžåœããŸãã
UBS Financial Services, Inc.ã¯6.12Kæ ªãä¿æããŠãããããã¯å šäœã®0.12%ã«çžåœããŸãã
111 Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
î111 Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
First Pharmacia International
Susquehanna International Group, LLP
Renaissance Technologies LLC
First Pharmacia International
Susquehanna International Group, LLP
Renaissance Technologies LLC
111 IncïŒYIïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ã111 Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯42瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ1.21Mã§ãå
šäœã®23.79%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-15.54%å¢å ããŠããŸãã
111 Incã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2025Q1ã«ãããŠãProduct Revenueséšéã111 Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯3.51Bã§ãå
šåçã®99.44%ãå ããŠããŸãã
